Skip to content

Health In Tech, Inc.: 10-Q filed 2025-11-12

What Health In Tech, Inc. reported in its quarterly report filed 2025-11-12 (fiscal Q3 2025): 38 published measures, 113 facts as tagged in accession 0001213900-25-109379.

This filing

Form
10-Q (quarterly report)
Filed
2025-11-12
Fiscal period
fiscal Q3 2025
Accession
0001213900-25-109379 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Health In Tech, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-09-3022,755,844USD
At 2024-12-3115,768,489USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-09-305,596,881USD
At 2024-12-312,599,461USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-09-3017,158,963USD
At 2025-06-3016,423,603USD
At 2025-03-3114,160,791USD
At 2024-12-3113,169,028USD
At 2024-09-306,907,855USD
At 2024-06-306,531,769USD
At 2024-03-316,193,762USD
At 2023-12-316,093,226USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2025-09-308,023,613USD
At 2024-12-317,849,248USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-07-01 to 2025-09-30452,176USD92
2025-01-01 to 2025-09-301,581,399USD273
2025-04-01 to 2025-06-30630,631USD91
2025-01-01 to 2025-03-31498,592USD90
2024-07-01 to 2024-09-30376,086USD92
2024-01-01 to 2024-09-30814,629USD274
2024-04-01 to 2024-06-30338,007USD91
2024-01-01 to 2024-03-31100,536USD91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-01-01 to 2025-09-302,682,602USD273
2024-01-01 to 2024-09-302,707,376USD274

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2025-07-01 to 2025-09-308,490,093USD92
2025-01-01 to 2025-09-3025,818,926USD273
2024-07-01 to 2024-09-304,458,921USD92
2024-01-01 to 2024-09-3014,586,342USD274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2025-01-01 to 2025-09-30-150,024USD273
2024-01-01 to 2024-09-30-3,081,864USD274

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2025-01-01 to 2025-09-30-2,358,213USD273
2024-01-01 to 2024-09-30-294,634USD274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-09-305,522,795USD
At 2024-12-313,941,396USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2025-07-01 to 2025-09-3056,432,407shares92
2025-01-01 to 2025-09-3055,484,860shares273
2024-07-01 to 2024-09-3051,769,358shares92
2024-01-01 to 2024-09-3051,769,358shares274

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2025-07-01 to 2025-09-3058,774,334shares92
2025-01-01 to 2025-09-3057,477,873shares273
2024-07-01 to 2024-09-3051,769,358shares92
2024-01-01 to 2024-09-3051,769,358shares274

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2025-07-01 to 2025-09-300.01USD/shares92
2025-01-01 to 2025-09-300.03USD/shares273
2024-07-01 to 2024-09-300.01USD/shares92
2024-01-01 to 2024-09-300.02USD/shares274

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-07-01 to 2025-09-300.01USD/shares92
2025-01-01 to 2025-09-300.03USD/shares273
2024-07-01 to 2024-09-300.01USD/shares92
2024-01-01 to 2024-09-300.02USD/shares274

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2025-07-01 to 2025-09-30148,046USD92
2025-01-01 to 2025-09-30536,514USD273
2024-07-01 to 2024-09-3030,653USD92
2024-01-01 to 2024-09-30185,119USD274

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2025-01-01 to 2025-09-301,493,686USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-09-3015,047,213USD
At 2024-12-3110,783,764USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-09-305,238,241USD
At 2024-12-312,130,974USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2025-09-30868,628USD
At 2024-12-311,647,103USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2025-07-01 to 2025-09-304,650,293USD92
2025-01-01 to 2025-09-3015,109,834USD273
2024-07-01 to 2024-09-303,040,411USD92
2024-01-01 to 2024-09-3010,335,836USD274

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2025-07-01 to 2025-09-305,143,816USD92
2025-01-01 to 2025-09-3016,809,085USD273
2024-07-01 to 2024-09-303,479,293USD92
2024-01-01 to 2024-09-3011,642,076USD274

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2025-07-01 to 2025-09-303,346,277USD92
2025-01-01 to 2025-09-309,009,841USD273
2024-07-01 to 2024-09-30979,628USD92
2024-01-01 to 2024-09-302,944,266USD274

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2025-07-01 to 2025-09-30235,819USD92
2025-01-01 to 2025-09-301,356,149USD273
2024-07-01 to 2024-09-30718,424USD92
2024-01-01 to 2024-09-302,180,246USD274

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2025-09-308,023,613USD
At 2024-12-317,849,248USD
At 2024-09-301,747,228USD
At 2023-12-312,416,350USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2025-09-30157,122USD
At 2024-12-31206,269USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2025-09-30157,600USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2025-09-302,117,854USD
At 2024-12-31787,161USD

Net deferred tax liabilities

Deferred tax liabilities net of related assets under this concept. The amount reflects timing differences and is not tax currently due.

PeriodValueUnitDays
At 2025-09-30274,809USD
At 2024-12-31328,676USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2025-07-01 to 2025-09-30600,222USD92
2025-01-01 to 2025-09-302,117,913USD273
2024-07-01 to 2024-09-30406,739USD92
2024-01-01 to 2024-09-30999,748USD274

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2025-07-01 to 2025-09-303,451,907USD92
2025-01-01 to 2025-09-3010,474,125USD273
2024-07-01 to 2024-09-301,813,520USD92
2024-01-01 to 2024-09-305,629,393USD274

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2025-01-01 to 2025-09-30489,947USD273
2024-01-01 to 2024-09-30405,158USD274

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

PeriodValueUnitDays
2024-07-01 to 2024-09-30165,000USD92
2024-01-01 to 2024-09-30495,000USD274

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2025-07-01 to 2025-09-30106,699USD92
2025-01-01 to 2025-09-30418,662USD273
2024-07-01 to 2024-09-30-32,143USD92
2024-01-01 to 2024-09-30-306,492USD274

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

PeriodValueUnitDays
2025-01-01 to 2025-09-30-53,867USD273
2024-01-01 to 2024-09-30-86,992USD274

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2025-01-01 to 2025-09-30823,323USD273
2024-01-01 to 2024-09-30340,787USD274

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2025-01-01 to 2025-09-308,214,000USD273

Operating lease payments

Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.

PeriodValueUnitDays
2025-07-01 to 2025-09-3020,794USD92
2025-01-01 to 2025-09-3062,381USD273

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2025-01-01 to 2025-09-30-776,574USD273
2024-01-01 to 2024-09-30-1,302,733USD274

Inspect the source

Entity
Health In Tech, Inc. / CIK 0002019505
Captured
2026-09-21T17:39:10.146Z
SEC response SHA-256
7a2cd05afeb8eb831499b687a8ce72a034af512cd3690655037fb995a38c0e02

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0002019505.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))